Based on the FDA approval of pembrolizumab as second-line therapy for PD-L1+ cervical cancer and microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors, pembrolizumab is included in the National Comprehensive Cancer Network (NCCN) guidelines for vulvar cancer. This evidence concerns the gene CD274 and vulva cancer.